IQVIA Holdings Inc. $IQV Shares Sold by Platinum Investment Management Ltd.

Platinum Investment Management Ltd. lowered its stake in IQVIA Holdings Inc. (NYSE:IQV) by 92.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 26,708 shares of the medical research company’s stock after selling 340,977 shares during the period. IQVIA makes up about 1.4% of Platinum Investment Management Ltd.’s investment portfolio, making the stock its 18th largest holding. Platinum Investment Management Ltd.’s holdings in IQVIA were worth $6,020,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of IQVIA by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock valued at $4,429,426,000 after buying an additional 159,899 shares in the last quarter. Geode Capital Management LLC boosted its holdings in IQVIA by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company’s stock worth $982,272,000 after purchasing an additional 24,453 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in IQVIA by 16.2% in the fourth quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company’s stock worth $856,468,000 after purchasing an additional 528,753 shares in the last quarter. Alliancebernstein L.P. boosted its holdings in IQVIA by 1.2% in the third quarter. Alliancebernstein L.P. now owns 3,597,572 shares of the medical research company’s stock worth $683,323,000 after purchasing an additional 41,643 shares in the last quarter. Finally, Boston Partners bought a new stake in IQVIA in the third quarter worth $676,698,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on IQV shares. Barclays upgraded shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price target for the company in a report on Friday, March 6th. TD Cowen raised shares of IQVIA from a “hold” rating to a “buy” rating and increased their price target for the stock from $174.00 to $213.00 in a research report on Monday, March 9th. Mizuho set a $215.00 price target on shares of IQVIA in a research report on Monday, February 23rd. Royal Bank Of Canada assumed coverage on shares of IQVIA in a report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price objective for the company. Finally, Morgan Stanley set a $225.00 price objective on shares of IQVIA in a report on Thursday, May 7th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $224.13.

IQVIA Price Performance

Shares of IQV stock opened at $181.10 on Friday. The firm has a market capitalization of $30.23 billion, a price-to-earnings ratio of 22.44, a price-to-earnings-growth ratio of 1.55 and a beta of 1.21. IQVIA Holdings Inc. has a 12-month low of $153.01 and a 12-month high of $247.04. The firm has a fifty day moving average of $173.56 and a 200-day moving average of $193.68. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same period in the previous year, the firm posted $2.70 EPS. The firm’s revenue was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 11.6 earnings per share for the current year.

IQVIA declared that its Board of Directors has approved a share buyback plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board believes its shares are undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.